AccuStem Sciences Limited
ACMSY
Other OTC0.13
USD
-0.01
- -
CIK
0001850767
ISIN
US00442Y1010
CUSIP
00442Y101
Return %
Stock
S&P500
1Y
- -
26.84
3Y
- -
77.03
5Y
-18.75
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 107 Cheapside London United Kingdom EC2V 6DN
- IPO Date
- Jul 21, 2021
- CIK
- 0001850767
- Website
- accustem.com
- Similar Companies
- Business
- AccuStem Sciences, Inc. AccuStem Sciences, Inc. (OTCQB: ACUT) is a clinical-stage diagnostics company that develops and commercializes genomic tests supporting decision-making across the oncology care continuum, from cancer screening and diagnosis to treatment planning and monitoring; its lead product candidates include the proprietary StemPrintER assay, a 20-gene prognostic tool predicting distant recurrence risk in luminal (ER+/HER2-negative) early-stage breast cancer patients, and the MicroRNA Signature Classifier (MSC) test, which stratifies lung nodules identified by low-dose computed tomography to distinguish benign from malignant cases and reduce false positives; the company also offers ancillary services such as hereditary genetic testing and somatic mutation analysis to provide comprehensive treatment insights for physicians and patients worldwide. Founded in 2020 as a spinoff from Tiziana Life Sciences plc to commercialize oncology diagnostics leveraging tumor stemness biology applicable across tumor types, AccuStem maintains headquarters in New York, New York, with a wholly-owned subsidiary, StemPrintER Sciences Limited, and operates primarily in the United States and United Kingdom. Recent developments include the March 2025 acquisition of proprietary rights to the MSC lung cancer screening test, originally validated in trials showing a five-fold reduction in LDCT false positives; expanded strategic partnerships with EmeritusDX announced in April 2025 to commercialize MSC with a planned 2026 rollout via CLIA-certified labs, and further in September 2025 to broaden blood-based testing capabilities, supporting EmeritusDX's 35% sales force expansion and launch of the Syntara platform for hematologic disease treatment strategies.